Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors

Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors
A Phase 1/2a trial of Immix Biopharma’s IMX-110, a combination treatment targeting advanced solid tumors, including ovarian cancer, has received the necessary ethics board approval to begin. The trial (NCT03382340) will explore the safety, tolerability, and pharmacokinetics (how the body metabolizes, distributes, and excretes a medicine) of IMX-110 in patients with a variety of advanced

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *